ATLANTA – CAR T cells are currently capable of making a giant difference, but only to tiny numbers of patients. But at the annual meeting of the American Association for Cancer Research, both phase I trial and novel preclinical approaches were on view that could bring the approach to more indications with larger numbers of patients.